van der Ark-Vonk, Ellen M.
Puijk, Mike V.
Pasterkamp, Gerard
van der Laan, Sander W.
Funding for this research was provided by:
Netherlands CardioVascular Research Initiative of the Netherlands Heart Foundation (CVON 2011/B019, CVON 2011/B019)
Fondation Leducq (PlaqOmics, PlaqOmics)
HORIZON EUROPE Framework Programme (MIRACLE, 101115381, MIRACLE, 101115381)
Horizon 2020 Framework Programme (TO_AITION, 848146, TO_AITION, 848146)
HealthHolland PPP Allowance (Getting the Perfect Image)
ERA-CVD (druggable-MI-targets, 01KL1802)
HORIZON EUROPE European Research Council (NextGen, 101136962)
EWUU (PlaqAI)
Article History
Accepted: 5 March 2024
First Online: 3 May 2024
Declarations
:
: Dr. Sander W. van der Laan and prof. dr. Gerard Pasterkamp have received Roche funding for unrelated work. Roche had no part in this study, neither in the conception, design, and execution of this study, nor in the preparation and contents of this manuscript. The other authors have no disclosures to report.
: Some data reported in this review are derived from the Athero-Express Biobank Study, an ongoing multi-center cohort study as described before []. The local medical ethics committee of the respective hospitals approved of this study, all patients provided written consent, and the study adheres to the guidelines of the Helsinki Declaration.